Patents by Inventor Brian M. Gallagher

Brian M. Gallagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8835441
    Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: September 16, 2014
    Assignee: Amgen Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • Patent number: 8572975
    Abstract: A combustion turbine engine that includes: a compressor; a combustor that receives fuel from a fuel line; a turbine; a heat exchange portion comprising a portion of the fuel line in heat transfer relationship with a heat source for heating the fuel; a rapid heating value meter disposed to test the heating value of the fuel that is configured to provide heating value test results within approximately 1 minute; a cold leg bypass comprising a fuel line that bypasses the heat exchange portion, the cold leg bypass being connected to the fuel line at an upstream fork and at a fuel mixing junction; and valves for controlling the fuel being directed through the heat exchange portion and the fuel being direct through the cold leg bypass; wherein the length of fuel line between the fuel mixing junction and the combustor is less than 20 meters.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: November 5, 2013
    Assignee: General Electric Company
    Inventors: Timothy R. Bilton, Dean M. Erickson, Brian M. Gallagher, Korey F. Rendo, John V. Hains
  • Publication number: 20120015920
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, JR., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • Publication number: 20100307158
    Abstract: A combustion turbine engine that includes: a compressor; a combustor that receives fuel from a fuel line; a turbine; a heat exchange portion comprising a portion of the fuel line in heat transfer relationship with a heat source for heating the fuel; a rapid heating value meter disposed to test the heating value of the fuel that is configured to provide heating value test results within approximately 1 minute; a cold leg bypass comprising a fuel line that bypasses the heat exchange portion, the cold leg bypass being connected to the fuel line at an upstream fork and at a fuel mixing junction; and valves for controlling the fuel being directed through the heat exchange portion and the fuel being direct through the cold leg bypass; wherein the length of fuel line between the fuel mixing junction and the combustor is less than 20 meters.
    Type: Application
    Filed: June 8, 2009
    Publication date: December 9, 2010
    Inventors: Timothy R. Bilton, Dean M. Erickson, Brian M. Gallagher, Korey F. Rendo, John V. Hains
  • Publication number: 20100249102
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: April 6, 2010
    Publication date: September 30, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur Taveras
  • Patent number: 7795245
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: September 14, 2010
    Assignee: Atlantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essors, Joshua Van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
  • Patent number: 7749996
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: July 6, 2010
    Assignee: Alantos Pharmaceutical Holdings, Inc.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, Jr., Irving Sucholeiki, Arthur Taveras
  • Patent number: 7713966
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: May 11, 2010
    Assignee: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Jr., Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgürtel, Bert Nolte, Arthur Taveras
  • Publication number: 20100113446
    Abstract: The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.
    Type: Application
    Filed: January 5, 2010
    Publication date: May 6, 2010
    Inventors: Brian M. Gallagher, JR., Eric Carlson, Qian Chen, Heather Davis, Shawn Schiller, Christina Shaffer, Mark Spyvee, Nancy Wong
  • Publication number: 20100093842
    Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.
    Type: Application
    Filed: August 26, 2009
    Publication date: April 15, 2010
    Inventors: Brian M. Gallagher, JR., Charles Johannes, Xiang-Yi Li, Marc Pesant, Hongjuan Zhao, Kozo Akasaka, Francis G. Fang
  • Publication number: 20100087420
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: December 4, 2009
    Publication date: April 8, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur G. Taveras
  • Patent number: 7666875
    Abstract: The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 23, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Brian M. Gallagher, Jr., Eric Carlson, Qian Chen, Heather Davis, Shawn Schiller, Christina Shaffer, Mark Spyvee, Nancy Wong
  • Publication number: 20090312312
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: February 12, 2009
    Publication date: December 17, 2009
    Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.
    Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
  • Publication number: 20080261968
    Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: October 23, 2008
    Inventors: Christian Gege, Matthias Schneider, Carine Chevrier, Hongbo Deng, Irving Sucholeiki, Brian M. Gallagher, Michael Bosies, Christoph Steeneck, Xinyuan Wu, Matthias Hochgurtel, Bert Nolte, Arthur Taveras
  • Publication number: 20080221095
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Carine Chevrier, Brian M. Gallagher, Arthur Taveras
  • Publication number: 20080221128
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Carine Chevrier, Brian M. Gallagher, Arthur Taveras
  • Publication number: 20080207607
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 28, 2008
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras
  • Publication number: 20080176870
    Abstract: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: July 24, 2008
    Inventors: Bert Nolte, Irving Sucholeiki, Tim Feuerstein, Brian M. Gallagher, Xinyuan Wu, Christoph Steeneck, Christian Gege, Hongbo Deng, Joshua Van Veldhuizen, Arthur Taveras